Patents by Inventor Thomas C. VanCott

Thomas C. VanCott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Truncated HIV envelope proteins (ENV), methods and compositions related thereto
    Patent number: 10081658
    Abstract: The instant application provides methods and related compositions pertaining to novel HIV envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel HIV envelope nucleic acid and protein sequences suitable, for example, as vaccines against HIV.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: September 25, 2018
    Assignees: Advanced BioScience Laboratories, Inc., The United States of America as Represented by the Secretary of the Army, The Henry M. Jackson Foundation for the Advancement of Military Medicines, Inc.
    Inventors: Vaniambadi Kalyanaraman, Stephen Whitney, Thomas C. VanCott, Victoria Polonis, Carl Alving, Gary R. Matyas, Mangala Rao, Mary Marovich, Francine McCutchan, Sodsai Tovanabutra, Eric Sanders-Buell
  • TRUNCATED HIV ENVELOPE PROTEINS (ENV), METHODS AND COMPOSITIONS RELATED THERETO
    Publication number: 20140220107
    Abstract: The instant application provides methods and related compositions pertaining to novel HIV envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel HIV envelope nucleic acid and protein sequences suitable, for example, as vaccines against HIV.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 7, 2014
    Applicants: ADVANCED BIOSCIENCE LABORATORIES, INC., HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, THE GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY
    Inventors: Vaniambadi Kalyanaraman, Stephen Whitney, Thomas C. Vancott, Victoria Polonis, Carl Alving, Gary R. Matyas, Mangala Rao, Mary Marovich, Francine McCutchan, Sodsai Tovanabutra, Eric Sanders-Buell
  • MVA expressing modified HIV envelope, GAG, and POL genes
    Publication number: 20110159036
    Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
    Type: Application
    Filed: October 19, 2007
    Publication date: June 30, 2011
    Inventors: Bernard Moss, Patricia L. Earl, Linda Wyatt, Leigh Anne Eller, Thomas C. VanCott, Matthew Edward Harris
  • MVA expressing modified HIV envelope, gag, and pol genes
    Patent number: 7303754
    Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: December 4, 2007
    Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of the Army
    Inventors: Bernard Moss, Patricia L. Earl, Linda Wyatt, Leigh Anne Eller, Thomas C. VanCott, Matthew Edward Harris
  • Protein and peptide vaccines for inducing mucosal immunity
    Publication number: 20020155120
    Abstract: A novel vaccine composition combines a protein or peptide antigen, optionally added hydrophobic material and an immunopotentiating membranous carrier which together preserve the antigenic integrity of the protein or peptide epitopes while at the same time enhancing their immunogenicity. Administration of this composition to a subject provokes a protective immune response comprising secretory neutralizing antibodies present in various mucosal sites in the body. This vaccine and the process for using it is intended for use against pathogenic organisms, in particular those causing sexually transmitted diseases or mucosally transmitted diseases. Such organisms include bacteria and enveloped viruses, particularly HIV-1.
    Type: Application
    Filed: August 21, 2001
    Publication date: October 24, 2002
    Inventors: George H. Lowell, Thomas C. Vancott, Deborah L. Birx